Regular
NAV (05-Sep-24)
Returns (Since Inception)
Fund Size
₹4,500 Cr
Expense Ratio
1.94%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+60.98%
+54.79% (Cat Avg.)
3 Years
+21.39%
+18.09% (Cat Avg.)
5 Years
+31.96%
+29.12% (Cat Avg.)
Since Inception
+24.56%
— (Cat Avg.)
Equity | ₹4,301.32 Cr | 95.58% |
Others | ₹198.93 Cr | 4.42% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹687.82 Cr | 15.28% |
Dr Reddy's Laboratories Ltd | Equity | ₹306.94 Cr | 6.82% |
Cipla Ltd | Equity | ₹303.66 Cr | 6.75% |
Aurobindo Pharma Ltd | Equity | ₹244.93 Cr | 5.44% |
Treps | Cash - Repurchase Agreement | ₹215.61 Cr | 4.79% |
Lupin Ltd | Equity | ₹212.32 Cr | 4.72% |
Apollo Hospitals Enterprise Ltd | Equity | ₹203.7 Cr | 4.53% |
Mankind Pharma Ltd | Equity | ₹183.8 Cr | 4.08% |
Gland Pharma Ltd | Equity | ₹173.45 Cr | 3.85% |
Divi's Laboratories Ltd | Equity | ₹173.42 Cr | 3.85% |
Alkem Laboratories Ltd | Equity | ₹149.5 Cr | 3.32% |
HealthCare Global Enterprises Ltd | Equity | ₹106.78 Cr | 2.37% |
AstraZeneca Pharma India Ltd | Equity | ₹94.54 Cr | 2.10% |
Zydus Lifesciences Ltd | Equity | ₹90.84 Cr | 2.02% |
Shilpa Medicare Ltd | Equity | ₹87.82 Cr | 1.95% |
Pfizer Ltd | Equity | ₹86.27 Cr | 1.92% |
Fortis Healthcare Ltd | Equity | ₹77.55 Cr | 1.72% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹76.29 Cr | 1.70% |
FDC Ltd | Equity | ₹73.47 Cr | 1.63% |
Glenmark Life Sciences Ltd | Equity | ₹71.08 Cr | 1.58% |
Windlas Biotech Ltd | Equity | ₹70.89 Cr | 1.58% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹67.16 Cr | 1.49% |
Thyrocare Technologies Ltd | Equity | ₹62.54 Cr | 1.39% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹59.21 Cr | 1.32% |
Glenmark Pharmaceuticals Ltd | Equity | ₹55.64 Cr | 1.24% |
Star Health and Allied Insurance Co Ltd | Equity | ₹54.01 Cr | 1.20% |
Wockhardt Ltd | Equity | ₹53.53 Cr | 1.19% |
Krsnaa Diagnostics Ltd | Equity | ₹53.04 Cr | 1.18% |
HDFC Life Insurance Company Limited | Equity | ₹52.65 Cr | 1.17% |
SRF Ltd | Equity | ₹49.15 Cr | 1.09% |
Blue Jet Healthcare Ltd | Equity | ₹46.88 Cr | 1.04% |
Vijaya Diagnostic Centre Ltd | Equity | ₹42.85 Cr | 0.95% |
Procter & Gamble Health Ltd | Equity | ₹42.74 Cr | 0.95% |
Vinati Organics Ltd | Equity | ₹40.64 Cr | 0.90% |
Emcure Pharmaceuticals Ltd | Equity | ₹38.87 Cr | 0.86% |
Net Current Assets | Cash | ₹-36.69 Cr | 0.82% |
Fine Organic Industries Ltd Ordinary Shares | Equity | ₹34.22 Cr | 0.76% |
Ajanta Pharma Ltd | Equity | ₹32.65 Cr | 0.73% |
Cash Margin - Derivatives | Cash - Collateral | ₹20.01 Cr | 0.44% |
Unichem Laboratories Ltd | Equity | ₹16.43 Cr | 0.37% |
Laxmi Organic Industries Ltd | Equity | ₹12.2 Cr | 0.27% |
Rainbow Childrens Medicare Ltd | Equity | ₹11.85 Cr | 0.26% |
Large Cap Stocks
43.58%
Mid Cap Stocks
24.24%
Small Cap Stocks
26.90%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹4,058.45 Cr | 90.18% |
Basic Materials | ₹136.21 Cr | 3.03% |
Financial Services | ₹106.66 Cr | 2.37% |
Standard Deviation
This fund
15.38%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.96
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Since May 2020
Since July 2022
ISIN | INF109KC1GE9 | Expense Ratio | 1.94% | Exit Load | 1.00% | Fund Size | ₹4,500 Cr | Age | 12 Jul 2018 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
Total AUM
₹8,56,645 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk